Monostars: An Aid to Choosing an Antiepileptic Drug as Monotherapy

This article describes a flexible, dynamic system for comparing antiepileptic drugs (AEDs) as monotherapy, taking into account the needs of the patient and the characteristics of the treatment. Because differences in efficacy between AEDs cannot readily be demonstrated in regulatory clinical trials, safety is of paramount importance. Each drug has been judged across 11 criteria. These include knowledge of mechanism of action, suitable pharmacokinetics, drug interactions, delineated range of efficacy, ease of titration, idiosyncratic reactions, sedative burden, neuropsychiatric profile, teratogenic potential, and the likelihood of producing long‐term side effects. The final consideration relates to how “comfortable” the doctor is with prescribing the drug as monotherapy. Scores of ‐1 (drawback), 0 (neutral/unknown), or +1 (advantage) have been allocated under each category, depending on current knowledge and clinical experience. The sum of the individual scores determines the awarding of “stars.” In addition, the positive and negative features of each AED, when used as monotherapy, are highlighted. A range of established and new AEDs has been examined using the “monostars” method, including phenobarbital, phenytoin, carbamazepine, sodium valproate, lamotrigine, gabapentin, oxcarbazepine, and vigabatrin. Scores can be adjusted as new information comes to light. Other agents can be added when suitable monotherapy data become available. This analysis supports the contention that choice of treatment in newly diagnosed epilepsy should take into consideration the patient's age, sex, general health, coexisting disabilities, concomitant medication, and life style. Seizure type, syndrome, and the AED's pharmacology, efficacy, and safety profile should also be considered. Because dosing is often modest, cost should rarely be the overriding factor in choosing a drug for a patient with newly diagnosed epilepsy in the developed world. With these criteria, some of the newer AEDs have potentially more to offer the patient as monotherapy than do the established agents.

[1]  D. Chadwick,et al.  Outcomes After Seizure Recurrence in People with Well‐Controlled Epilepsy and the Factors That Influence It , 1996, Epilepsia.

[2]  M. Brodie,et al.  Felbamate: 1997 Update , 1997, Epilepsia.

[3]  Y. Løyning,et al.  A double-blind study comparing oxcarbazepine and carbamazepine in patients with newly diagnosed, previously untreated epilepsy , 1989, Epilepsy Research.

[4]  M. Brodie,et al.  Lamotrigine versus other antiepileptic drugs: a star rating system is born. , 1994, Epilepsia.

[5]  M. Brodie,et al.  Lamotrigine substitution study: evidence for synergism with sodium valproate? , 1997, Epilepsy Research.

[6]  M. Knip,et al.  Obesity and endocrine disorders in women taking valproate for epilepsy , 1996, Annals of neurology.

[7]  B. Wilder.  How About the New Antiepileptic Drugs? , 1994, Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques.

[8]  M. Morrell.  The New Antiepileptic Drugs and Women: Efficacy, Reproductive Health, Pregnancy, and Fetal Outcome , 1996, Epilepsia.

[9]  A. Beydoun.  Monotherapy Trials of New Antiepileptic Drugs , 1997, Epilepsia.

[10]  M. Brodie,et al.  High dose gabapentin in refractory partial epilepsy: clinical observations in 50 patients , 1998, Epilepsy Research.

[11]  J. Cramer,et al.  Comparison of carbamazepine, phenobarbital, phenytoin, and primidone in partial and secondarily generalized tonic-clonic seizures. , 1985, The New England journal of medicine.

[12]  M. Brodie.  Lamotrigine – An Update , 1996, Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques.

[13]  J. Gotman,et al.  EEG Slow Waves and Memory Performance During the Intracarotid Amobarbital Test , 1994, Epilepsia.

[14]  P. Riekkinen,et al.  Vigabatrin vs carbamazepine monotherapy in patients with newly diagnosed epilepsy. A randomized, controlled study. , 1995, Archives of neurology.

[15]  M. Brodie,et al.  Double-blind substitution of vigabatrin and valproate in carbamazepine-resistant partial epilepsy , 1999, Epilepsy Research.

[16]  T. Steiner.  Comparison of lamotrigine (Lamictal) and phenytoin monotherapy in newly diagnosed epilepsy [Abstract] , 1994 .

[17]  M. Brodie,et al.  Established antiepileptic drugs , 1997, Seizure.

[18]  M. Brodie,et al.  Double-blind comparison of lamotrigine and carbamazepine in newly diagnosed epilepsy , 1995, The Lancet.

[19]  A. Marson,et al.  New antiepileptic drugs: a systematic review of their efficacy and tolerability , 1996, BMJ.

[20]  S. Kochen,et al.  A double-blind controlled clinical trial of oxcarbazepine versus phenytoin in adults with previously untreated epilepsy 1 This study was carried out on behalf of the International Adult Oxcarbazepine/Phenytoin Trial Group (see Appendix A). 1 , 1997, Epilepsy Research.

[21]  D. Chadwick.  Monotherapy Clinical Trials of New Antiepileptie Drugs: Design, Indications, and Controversies , 1997, Epilepsia.

[22]  B. Steinhoff,et al.  A double-blind controlled clinical trial: oxcarbazepine versus sodium valproate in adults with newly diagnosed epilepsy 1 This work was carried out on behalf of the International Oxcarbazepine/Valproate Trial Group (see Appendix A). 1 , 1997, Epilepsy Research.

[23]  M. Brodie.  Antiepileptic drugs, clinical trials, and the marketplace , 1996, The Lancet.

[24]  D. Schmidt,et al.  Monotherapy versus Polytherapy in Epilepsy , 1995 .

[25]  M. Brodie,et al.  New antiepileptic drugs. , 1996, The New England journal of medicine.

[26]  K. Kashihara,et al.  Regional Increases in Brain‐Derived Neurotrophic Factor and Nerve Growth Factor mRNAs During Amygdaloid Kindling, But Not in Acidic and Basic Fibroblast Growth Factor mRNAs , 1996, Epilepsia.

[27]  M. Morrell,et al.  Self‐Reported Sexual Function and Sexual Arousability in Women with Epilepsy , 1996, Epilepsia.

[28]  N. Fejerman,et al.  A double-blind controlled clinical trial of oxcarbazepine versus phenytoin in children and adolescents with epilepsy 1 This work was carried out on behalf of the International Pediatric Oxcarbazepine/Phenytoin Trial Group (Appendix A). 1 , 1997, Epilepsy Research.

[29]  H G Wieser,et al.  Commission on European Affairs: Appropriate Standards of Epilepsy Care Across Europe , 1997, Epilepsia.

[30]  W. Rosenfeld,et al.  Long‐Term Experience with Topiramate as Adjunctive Therapy and as Monotherapy in Patients with Partial Onset Seizures: Retrospective Survey of Open‐Label Treatment , 1997, Epilepsia.

[31]  T Eke,et al.  Retrospective study of concussive convulsions in elite Australian rules and rugby league footballers: phenomenology, aetiology, and outcome , 1997, BMJ.

[32]  J. Wada,et al.  Amygdaloid Kindling in the Japanese Monkey Macacafuscata: Pre‐ and Postictal Discharges. , 1996 .